dostęp płatny
Wskaźniki stanu zapalnego w depresji
- Uniwersytet Medyczny w Łodzi
- Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Wyszkowie
- Wojewódzki Szpital Zespolony w Skierniewicach
- Klinika Psychiatrii, Uniwersytet Medyczny w Białymstoku
dostęp płatny
Streszczenie
Streszczenie
Pełny tekst:
Dodaj do koszyka: 49,00 PLNSłowa kluczowe
depresja, stan zapalny, IFN-α, IFN-β, TNF-α, SSRI
Tytuł
Wskaźniki stanu zapalnego w depresji
Czasopismo
Numer
Typ artykułu
Artykuł przeglądowy
Strony
286-291
Opublikowany online
2023-01-09
Wyświetlenia strony
686
Wyświetlenia/pobrania artykułu
50
DOI
Rekord bibliograficzny
Psychiatria 2022;19(4):286-291.
Słowa kluczowe
depresja
stan zapalny
IFN-α
IFN-β
TNF-α
SSRI
Autorzy
Wojciech Grzegorz Wiese
Alicja Cichocka
Justyna Maria Krysztowiak-Wiese
Emil Bartosz Rozenek
Napoleon Waszkiewicz
- Lim GY, Tam WW, Lu Y, et al. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018; 8(1): 2861.
- Fried EI, Nesse RM. Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. BMC Med. 2015; 13(1): 72.
- Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization Seattle. 2016.
- Bortolato B, Hyphantis TN, Valpione S, et al. Depression in cancer: The many biobehavioral pathways driving tumor progression. Cancer Treat Rev. 2017; 52: 58–70.
- Windle M, Windle RC. Recurrent depression, cardiovascular disease, and diabetes among middle-aged and older adult women. J Affect Disord. 2013; 150(3): 895–902.
- Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904): 1575–1586.
- König H, König HH, Konnopka A. The excess costs of depression: a systematic review and meta-analysis. Epidemiol Psychiatr Sci. 2019; 29: e30.
- Galecki P. Psychiatria. Edra Urban & Partner, Wrocław 2018: 203.
- Komenda Główna Policji. Zamachy samobójcze od 2017 roku [Internet]. Statystyka. 2020. https://statystyka.policja.pl/st/wybrane-statystyki/zamachy-samobojcze/63803,Zamachy-samobojcze-od-2017-roku.html (17.11.2021).
- Główny Urząd Statystyczny. Rocznik Demograficzny 2020. https://stat.gov.pl/obszary-tematyczne/roczniki-statystyczne/roczniki-statystyczne/rocznik-demograficzny-2020,3,14.html (17.11.2021).
- Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965; 122(5): 509–522.
- Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019; 22(3): 343–352.
- Choi KW, Chen CY, Stein MB, et al. Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Assessment of Bidirectional Relationships Between Physical Activity and Depression Among Adults: A 2-Sample Mendelian Randomization Study. JAMA Psychiatry. 2019; 76(4): 399–408.
- Wray NR, Ripke S, Mattheisen M, et al. eQTLGen, 23andMe, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018; 50(5): 668–681.
- Tsang RSM, Mather KA, Sachdev PS, et al. Systematic review and meta-analysis of genetic studies of late-life depression. Neurosci Biobehav Rev. 2017; 75: 129–139.
- Fischer S, Macare C, Cleare AJ. Hypothalamic-pituitary-adrenal (HPA) axis functioning as predictor of antidepressant response-Meta-analysis. Neurosci Biobehav Rev. 2017; 83: 200–211.
- Markopoulou K, Fischer S, Papadopoulos A, et al. Comparison of hypothalamo-pituitary-adrenal function in treatment resistant unipolar and bipolar depression. Transl Psychiatry. 2021; 11(1): 244.
- Leong Bin Abdullah MF, Ng YP, Sidi HB. Depression and anxiety among traumatic brain injury patients in Malaysia. Asian J Psychiatr. 2018; 37: 67–70.
- Osborn AJ, Mathias JL, Fairweather-Schmidt AK, et al. Anxiety and comorbid depression following traumatic brain injury in a community-based sample of young, middle-aged and older adults. J Affect Disord. 2017; 213: 214–221.
- Roy D, Koliatsos V, Vaishnavi S, et al. Risk factors for new-onset depression after first-time traumatic brain injury. Psychosomatics. 2018; 59(1): 47–57.
- Raison CL, Borisov AS, Woolwine BJ, et al. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry. 2010; 15(5): 535–547.
- Felger JC, Cole SW, Pace TWW, et al. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue. Psychol Med. 2012; 42(8): 1591–1603.
- Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. 2001; 15(1): 7–24.
- Smith RS, Smith RS. The macrophage theory of depression. Med Hypotheses. 1991; 35(4): 298–306.
- Osimo EF, Baxter LJ, Lewis G, et al. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019; 49(12): 1958–1970.
- Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016; 21(12): 1696–1709.
- Smith KJ, Au B, Ollis L, et al. The association between C-reactive protein, Interleukin-6 and depression among older adults in the community: A systematic review and meta-analysis. Exp Gerontol. 2018; 102: 109–132.
- Haapakoski R, Mathieu J, Ebmeier KP, et al. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015; 49: 206–215.
- Tripathi A, Whitehead C, Surrao K, et al. Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway. Mol Psychiatry. 2021; 26(7): 3043–3059.
- Köhler CA, Freitas TH, Maes M, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017; 135(5): 373–387.
- Colasanto M, Madigan S, Korczak DJ. Depression and inflammation among children and adolescents: A meta-analysis. J Affect Disord. 2020; 277: 940–948.
- Martin-Subero M, Anderson G, Kanchanatawan B, et al. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr. 2016; 21(2): 184–198.
- Kurina LM, Goldacre MJ, Yeates D, et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health. 2001; 55(10): 716–720.
- Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004; 66(1): 79–84.
- Jiang M, Qin P, Yang Xu. Comorbidity between depression and asthma via immune-inflammatory pathways: a meta-analysis. J Affect Disord. 2014; 166: 22–29.
- Shen TC, Lin CL, Liao CH, et al. Major depressive disorder is associated with subsequent adult-onset asthma: a population-based cohort study. Epidemiol Psychiatr Sci. 2017; 26(6): 664–671.
- Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013; 52(12): 2136–2148.
- Pashaki MS, Mezel JA, Mokhtari Z, et al. The prevalence of comorbid depression in patients with diabetes: a meta-analysis of observational studies. Diabetes Metab Syndr. 2019; 13(6): 3113–3119.
- Hasan SS, Clavarino AM, Mamun AA, et al. Incidence and risk of diabetes mellitus associated with depressive symptoms in adults: evidence from longitudinal studies. Diabetes Metab Syndr. 2014; 8(2): 82–87.
- Su KP, Lai HC, Peng CY, et al. Interferon-alpha-induced depression: comparisons between early- and late-onset subgroups and with patients with major depressive disorder. Brain Behav Immun. 2019; 80: 512–518.
- Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012; 57(6): 1379–1390.
- Cooper CM, Godlewska B, Sharpley AL, et al. Interferon-α induces negative biases in emotional processing in patients with hepatitis C virus infection: a preliminary study. Psychol Med. 2018; 48(6): 998–1007.
- Sarkar S, Kemper J, Sarkar R, et al. Influence of gender on cytokine induced depression and treatment: gender aspects of IFN-α-induced depression. J Affect Disord. 2021; 292: 766–772.
- Chiu WC, Su YP, Su KP, et al. Recurrence of depressive disorders after interferon-induced depression. Transl Psychiatry. 2017; 7(2): e1026.
- Sun CF, Chiu WC, Chen PC, et al. Depression-free after Interferon-α exposure indicates less incidence of depressive disorder: A longitudinal study in Taiwan. Brain Behav Immun. 2020; 88: 125–131.
- Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019; 81: 24–40.
- Hestad KA, Engedal K, Whist JE, et al. Patients with depression display cytokine levels in serum and cerebrospinal fluid similar to patients with diffuse neurological symptoms without a defined diagnosis. Neuropsychiatr Dis Treat. 2016; 12: 817–822.
- Boufidou F, Lambrinoudaki I, Argeitis J, et al. CSF and plasma cytokines at delivery and postpartum mood disturbances. J Affect Disord. 2009; 115(1-2): 287–292.
- Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009; 66(3): 287–292.
- Wu Di, Zhang G, Zhao C, et al. Interleukin-18 from neurons and microglia mediates depressive behaviors in mice with post-stroke depression. Brain Behav Immun. 2020; 88: 411–420.
- Felger JC, Li Z, Haroon E, et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry. 2016; 21(10): 1358–1365.
- Lee S, Oh SS, Jang SI, et al. Sex Difference in the Association between High-sensitivity C-reactive Protein and Depression: The 2016 Korea National Health and Nutrition Examination Survey. Sci Rep. 2019; 9(1): 1918.
- Jung YE, Kang KY. Elevated hs-CRP level is associated with depression in younger adults: Results from the Korean National Health and Nutrition Examination Survey (KNHANES 2016). Psychoneuroendocrinology. 2019; 109: 104397.
- Tabatabaeizadeh SA, Abdizadeh MF, Meshkat Z, et al. There is an association between serum high-sensitivity C-reactive protein (hs-CRP) concentrations and depression score in adolescent girls. Psychoneuroendocrinology. 2018; 88: 102–104.
- Bliźniewska-Kowalska K, Szewczyk B, Gałecka M, et al. Is Interleukin 17 (IL-17) Expression A Common Point in the Pathogenesis of Depression and Obesity? J Clin Med. 2020; 9(12).
- Leighton SP, Nerurkar L, Krishnadas R, et al. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry. 2018; 23(1): 48–58.
- Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci. 2015; 128(13): 2213–2219.
- Sciacchitano S, Lavra L, Morgante A, et al. Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. Int J Mol Sci. 2018; 19(2).
- Melin EO, Dereke J, Thunander M, et al. Depression in type 1 diabetes was associated with high levels of circulating galectin-3. Endocr Connect. 2018; 7(6): 819–828.
- King DR, Salako DC, Arthur-Bentil SK, et al. Relationship between novel inflammatory biomarker galectin-3 and depression symptom severity in a large community-based sample. J Affect Disord. 2021; 281: 384–389.
- Dunlop BW, Kelley ME, Aponte-Rivera V, et al. PReDICT Team. Effects of patient preferences on outcomes in the predictors of remission in depression to individual and combined treatments (predict) study. Am J Psychiatry. 2017; 174(6): 546–556.
- Köhler-Forsberg O, N Lydholm C, Hjorthøj C, et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019; 139(5): 404–419.
- Kappelmann N, Lewis G, Dantzer R, et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018; 23(2): 335–343.
- Wang L, Wang R, Liu L, et al. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain Behav Immun. 2019; 79: 24–38.
- Więdłocha M, Marcinowicz P, Krupa R, et al. Effect of antidepressant treatment on peripheral inflammation markers - a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 80(Pt C): 217–226.
- Köhler CA, Freitas TH, Stubbs B, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. 2018; 55(5): 4195–4206.
- Strawbridge R, Arnone D, Danese A, et al. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015; 25(10): 1532–1543.
- Liu JJ, Wei YaB, Strawbridge R, et al. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol Psychiatry. 2020; 25(2): 339–350.
- Carlier A, Berkhof JG, Rozing M, et al. Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study. J Affect Disord. 2019; 256: 509–516.